340 related articles for article (PubMed ID: 27385486)
1. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
2. Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR.
Wu M; An J; Zheng Q; Xin X; Lin Z; Li X; Li H; Lu D
Oncotarget; 2016 Oct; 7(41):66525-66539. PubMed ID: 27167190
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
[TBL] [Abstract][Full Text] [Related]
4. The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.
Xiaoyu H; Yiru Y; Shuisheng S; Keyan C; Zixing Y; Shanglin C; Yuan W; Dongming C; Wangliang Z; Xudong B; Jie M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818780063. PubMed ID: 29916308
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1.
He CL; Bian YY; Xue Y; Liu ZX; Zhou KQ; Yao CF; Lin Y; Zou HF; Luo FX; Qu YY; Zhao JY; Ye ML; Zhao SM; Xu W
Sci Rep; 2016 Feb; 6():21524. PubMed ID: 26876154
[TBL] [Abstract][Full Text] [Related]
6. Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.
Cheng K; Hao M
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916907
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H
Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052
[TBL] [Abstract][Full Text] [Related]
8. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.
Zhu H; Wu J; Zhang W; Luo H; Shen Z; Cheng H; Zhu X
Sci Rep; 2016 Aug; 6():30788. PubMed ID: 27492148
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells.
Zhou Z; Li M; Zhang L; Zhao H; Şahin Ö; Chen J; Zhao JJ; Songyang Z; Yu D
Cancer Res; 2018 May; 78(9):2248-2261. PubMed ID: 29440169
[TBL] [Abstract][Full Text] [Related]
10. Distinctive role of SIK1 and SIK3 isoforms in aerobic glycolysis and cell growth of breast cancer through the regulation of p53 and mTOR signaling pathways.
Ponnusamy L; Manoharan R
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118975. PubMed ID: 33545220
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
[TBL] [Abstract][Full Text] [Related]
12. The multifaceted regulation and functions of PKM2 in tumor progression.
Li Z; Yang P; Li Z
Biochim Biophys Acta; 2014 Dec; 1846(2):285-96. PubMed ID: 25064846
[TBL] [Abstract][Full Text] [Related]
13. PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation.
Li T; Han J; Jia L; Hu X; Chen L; Wang Y
Protein Cell; 2019 Aug; 10(8):583-594. PubMed ID: 30887444
[TBL] [Abstract][Full Text] [Related]
14. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells.
Jiang Y; Wang Y; Wang T; Hawke DH; Zheng Y; Li X; Zhou Q; Majumder S; Bi E; Liu DX; Huang S; Lu Z
Nat Commun; 2014 Nov; 5():5566. PubMed ID: 25412762
[TBL] [Abstract][Full Text] [Related]
15. PKM2, cancer metabolism, and the road ahead.
Dayton TL; Jacks T; Vander Heiden MG
EMBO Rep; 2016 Dec; 17(12):1721-1730. PubMed ID: 27856534
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.
Cordani M; Oppici E; Dando I; Butturini E; Dalla Pozza E; Nadal-Serrano M; Oliver J; Roca P; Mariotto S; Cellini B; Blandino G; Palmieri M; Di Agostino S; Donadelli M
Mol Oncol; 2016 Aug; 10(7):1008-29. PubMed ID: 27118659
[TBL] [Abstract][Full Text] [Related]
17. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
18. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression.
Nemazanyy I; Espeillac C; Pende M; Panasyuk G
Biochem Soc Trans; 2013 Aug; 41(4):917-22. PubMed ID: 23863156
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
[TBL] [Abstract][Full Text] [Related]
20. Changes in PKM2 associate with prostate cancer progression.
Wong N; Yan J; Ojo D; De Melo J; Cutz JC; Tang D
Cancer Invest; 2014 Aug; 32(7):330-8. PubMed ID: 24884829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
